ANGN - Angion Vifor Pharma complete enrollment in mid-stage ANG-3777 study

Angion Biomedica (ANGN) and Vifor Pharma have completed enrollment for Angion’s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI).This indication is part of the ANG-3777 license agreement both parties signed in November 2020.The primary endpoint is mean area under the curve of the percent increase in serum creatinine above baseline, starting from 24 hours after the end of cardiopulmonary bypass surgery through day six.An additional important endpoint is the occurrence of Major Adverse Kidney Events at 90 days (MAKE 90).The company is planning to start Phase 3 registration trial of ANG-3777 for CSA-AKI in 2022, subject to the results of this Phase 2 trial as well as discussions with the FDA and other relevant health authorities.

For further details see:

Angion, Vifor Pharma complete enrollment in mid-stage ANG-3777 study